Second line

The Crawdad Festival 2024 - CAL EXPO

Retrieved on: 
Wednesday, January 24, 2024

SACRAMENTO, Calif., Jan. 24, 2024 /PRNewswire/ -- In 2023, The Crawdad Festival, LLC triumphantly launched "The Crawdad Festival" in Isleton, California, attracting an astounding crowd of over 70,000 participants.

Key Points: 
  • SACRAMENTO, Calif., Jan. 24, 2024 /PRNewswire/ -- In 2023, The Crawdad Festival, LLC triumphantly launched "The Crawdad Festival" in Isleton, California, attracting an astounding crowd of over 70,000 participants.
  • Bolstered by this resounding success, The Crawdad Festival, LLC decided to move the festival toCal Expo in Sacramento, California.
  • Join us for the 2nd annual Crawdad Festival, a community-oriented, multicultural, family event scheduled for Father's Day Weekend, on June 15th and 16th, 2024, at Cal Expo in Sacramento, California.
  • Dive into the vibrant Cal Expo atmosphere filled with Cajun cuisine, live music, and family activities over Father's Day Weekend.

Cellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024

Retrieved on: 
Thursday, November 2, 2023

FLORHAM PARK, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that top-line data from the pivotal trial in Waldenstrom’s macroglobulinemia (WM) will be released during the JP Morgan Healthcare conference the week of January 8, 2024.

Key Points: 
  • The PRIME designation was awarded based upon data from a pre-planned interim assessment in the pivotal study and six patients from the Phase 2a.
  • “We continue to collect and evaluate patient data from our pivotal trial and expect to announce top-line data the week of January 8, 2024.
  • We view this data announcement as a potentially transformational event for Cellectar and as such merits optimal market and industry awareness, which the JP Morgan conference provides.
  • Stockholders and other interested parties may participate in the conference call by dialing 1-888-886-7786 (in the U.S.) or 1-416-764-8658 (outside the U.S.).

ProPhase Labs Announces Substantial Growth Expectations for Pharmaloz Manufacturing Subsidiary due to Skyrocketing Demand for Pharmaloz Output.

Retrieved on: 
Tuesday, October 17, 2023

Garden City, NY, Oct. 17, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, today unveiled the substantial expansion strategy for its wholly-owned subsidiary, Pharmaloz Manufacturing, Inc. (PMI). Pharmaloz is a large lozenge manufacturing facility and Contract Development and Manufacturing Organization (CDMO) and is wholly owned by ProPhase Labs. Pharmaloz offers private label and other services to well-known brands, as well as manufacturing our own, proprietary products.

Key Points: 
  • Garden City, NY, Oct. 17, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, today unveiled the substantial expansion strategy for its wholly-owned subsidiary, Pharmaloz Manufacturing, Inc. (PMI).
  • Pharmaloz is a large lozenge manufacturing facility and Contract Development and Manufacturing Organization (CDMO) and is wholly owned by ProPhase Labs.
  • Pharmaloz offers private label and other services to well-known brands, as well as manufacturing our own, proprietary products.
  • Pharmaloz offers its customers ultra-high-quality products and sources from ingredient suppliers who provide us with top-quality ingredients.

Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing

Retrieved on: 
Monday, September 11, 2023

The financing was led by Rosalind Advisors with participation from AIGH Capital, ADAR1, Second Line, Nantahala Capital, AuGC, and other new and existing institutional investors.

Key Points: 
  • The financing was led by Rosalind Advisors with participation from AIGH Capital, ADAR1, Second Line, Nantahala Capital, AuGC, and other new and existing institutional investors.
  • Conversion of the Series E Preferred Stock into shares of common stock of the Company is subject to approval by the Company's stockholders.
  • Oppenheimer & Co. Inc. acted as the sole placement agent for the private placement.
  • Cellectar has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock underlying the Series E Preferred Stock.

Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing

Retrieved on: 
Tuesday, September 5, 2023

FLORHAM PARK, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced it has entered into a securities purchase agreement with certain institutional investors for a private placement financing (the “PIPE”) that is expected to result in gross proceeds of up to $102.9 million, including an initial funding of $24.5 million priced at the company’s common stock closing price on September 1, 2023 of $1.82 per share. The financing is being led by Rosalind Advisors with participation from AIGH Capital, ADAR1, Second Line, Nantahala Capital, AuGC, and other new and existing institutional investors.

Key Points: 
  • The financing is being led by Rosalind Advisors with participation from AIGH Capital, ADAR1, Second Line, Nantahala Capital, AuGC, and other new and existing institutional investors.
  • “This financing with current and new investor funds of up to $102.9 million reflects the significant value of our lead asset iopofosine and R&D pipeline,” said James Caruso, president and CEO of Cellectar.
  • “With the initial $24.5 million, we are able to fully fund all corporate activities through the completion of our pivotal trial and expected reporting of top-line data later this year.
  • Oppenheimer & Co. Inc. acted as the sole placement agent for the private placement.

The Bogota 'Metro' is one of the engines that drives the national economy

Retrieved on: 
Wednesday, March 22, 2023

It is estimated that the total value of these projects in the city, under the current administration reaches USD 12.1 million.

Key Points: 
  • It is estimated that the total value of these projects in the city, under the current administration reaches USD 12.1 million.
  • This is why Invest in Bogota has prioritized attracting investment in this project, to contribute to its success.
  • "We focus on these two countries because of their relevance and impact on historical investment in infrastructure projects in the Bogota Region.
  • Infrastructure is one of the sectors that have gained relevance in recent years, given the impact it generates on the national GDP.

Vietnam Tuberculosis Therapeutics Market Report to 2028 - Featuring Novartis Vietnam, Johnson & Johnson, Otsuka Pharmaceutical Vietnam JSC, Lupin and GSK Vietnam - ResearchAndMarkets.com

Retrieved on: 
Friday, September 30, 2022

The Vietnam tuberculosis therapeutics market is anticipated to register a robust growth in the forecast period, 2023-2027.

Key Points: 
  • The Vietnam tuberculosis therapeutics market is anticipated to register a robust growth in the forecast period, 2023-2027.
  • Besides, increasing investments and grants for tuberculosis therapeutics are boosting the growth of the Vietnam tuberculosis therapeutics market.
  • Rising government measures and growing public awareness of communicable illnesses are also expected to fuel the Vietnam tuberculosis therapeutics market.
  • The Vietnam tuberculosis therapeutics market is segmented on the basis of disease type, therapy, competitive landscape, and regional distribution.

Global Neoantigen Cancer Vaccine Market Analysis and Forecasts 2024-2031: Launch of First Neoantigen Vaccine Set to Generate $35.5 Million in Revenue in 2024 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 14, 2022

The neoantigen cancer vaccine market is projected to reach $1,988.5 million by 2031 from $35.5 million in 2024, at a compound annual growth rate (CAGR) of 77.73%.

Key Points: 
  • The neoantigen cancer vaccine market is projected to reach $1,988.5 million by 2031 from $35.5 million in 2024, at a compound annual growth rate (CAGR) of 77.73%.
  • The neoantigen cancer vaccine market is expected to generate $35.5 million in revenue in 2024, owing to the expected launch of the first neoantigen vaccine, DC vaccine in the market.
  • The emerging neoantigen cancer vaccines are segmented based on disease/application into lung cancer, urinary system cancer, melanoma, liver cancer, head and neck cancer, and blood and bone marrow cancer.
  • The emerging neoantigen cancer vaccines are segmented based on type of neovaccine into nucleic acid vaccine, peptide vaccine, and dendritic cell vaccine.

Winn-Dixie Continues Investment in Louisiana With $30,000 Donation to Krewe of Red Beans and Four Newly Remodeled Stores

Retrieved on: 
Tuesday, March 29, 2022

The four newly remodeled stores mark 24 Louisiana renewal investments made in the last five years by Winn-Dixies parent company, Southeastern Grocers.

Key Points: 
  • The four newly remodeled stores mark 24 Louisiana renewal investments made in the last five years by Winn-Dixies parent company, Southeastern Grocers.
  • Since July 28, 1956, Winn-Dixie has been deeply rooted in Louisiana communities and continues to invest in its local neighborhoods.
  • Founded in 1925, Winn-Dixie grocery stores, liquor stores and in-store pharmacies serve communities throughout five southeastern states Alabama, Florida, Georgia, Louisiana and Mississippi.
  • Winn-Dixie Stores, Inc. is a subsidiary of Southeastern Grocers, which is one of the largest conventional supermarket chains based in the Southeast.

Winn-Dixie Launches Community Donation Program Benefiting the Krewe of Red Beans and Feed the Second Line

Retrieved on: 
Monday, February 21, 2022

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    Winn-Dixie customers in Louisiana can round up their grocery bill total or make a donation of their choice at checkout through Mardi Gras Day (March 1) to support Feed the Second Line.
  • Joey Medina, Regional Vice President for Winn-Dixie, said, We are honored to continue our partnership with the Krewe of Red Beans and Feed the Second Line to provide essential support to the local musicians and artists who keep Louisianas traditions alive.
  • The Krewe of Red Beans purchased nearly $80,000 worth of groceries for 130 culture bearers, which include many elderly individuals in need in the community.
  • Additionally, the Krewe of Red Beans created nearly $400,000 worth of direct employment, including helping local musicians secure new jobs with their local Winn-Dixie.